4.4 Article

Cerebrospinal Fluid Profiles in Parkinson's Disease: No Accumulation of Glucosylceramide, but Significant Downregulation of Active Complement C5 Fragment

期刊

JOURNAL OF PARKINSONS DISEASE
卷 11, 期 1, 页码 221-232

出版社

IOS PRESS
DOI: 10.3233/JPD-202310

关键词

Parkinson's disease; complement; mass spectrometry; innate immunity; glycosphingolipids

资金

  1. JSPS KAKENHI Grant from the Ministry of Education, Culture, Sports, Science, and Technology (MEXT) of Japan [JP17K15608]
  2. Ministry of Education, Culture, Sports, Science, and Technology (MEXT) of Japan
  3. JSPS KAKENHI Grant from MEXT [JP17K15608]
  4. Research Grants for Intractable Diseases from the Ministry of Health, Labor, and Welfare of Japan

向作者/读者索取更多资源

The study revealed that C5a levels were downregulated in the CSF of PD patients and a specific glucosylceramide subspecies in CSF was associated with the immune status in PD.
Background: As mutations in glucocerebrosidase 1 (GBA1) are a major risk factor for Parkinson's disease (PD), decreased GBA1 activity might play an important role in the pathogenesis of the disease. However, there are currently no reports on glucosylceramide levels in the cerebrospinal fluid (CSF) in PD. Objective: We investigated whether glucosylceramide accumulation and abnormal immune status in the brain are associated with PD. Methods: We measured glucosylceramide by liquid chromatography-electrospray ionization-tandem mass spectrometry (LC-ESI-MS/MS) as well as levels of the active fragment of complement C5, C5a, in the CSF of 33 PD, 15 amyotrophic lateral sclerosis (ALS) and 22 neurologically normal control (NNC) subjects. Serum C5a levels in all PD and ALS cases and in a limited number of NNC subjects (n = 8) were also measured. Results: C5a levels in CSF were significantly downregulated in PD compared with NNC. Moreover, CSF C5a/serum C5a ratio showed pronounced perturbations in PD and ALS patients. LC-ESI-MS/MS revealed a statistically significant accumulation of a specific subspecies of glucosylceramide (d18 : 1/C23 : 0 acyl chain fatty acid) in ALS, but not in PD. Interestingly, CSF glucosylceramide (d18 : 1/C23 : 0) exhibited a significant correlation with CSF C5a levels in PD, but not ALS. No correlation was observed between C5a levels or glucosylceramide subspecies content and disease duration, levodopa equivalent daily dose or Hoehn & Yahr staging in PD. Conclusion: Our findings demonstrate complement dysregulation without glucosylceramide accumulation in PD CSF. Furthermore, we found an association between a specific glucosylceramide subspecies and immune status in PD.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.4
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
暂无数据